Service de Pharmacologie médicale, Centres Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Service Psychiatrie-Addictologie, Université Clermont Auvergne, CHU Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand, France.
Observatoire Français des Médicaments Antalgiques (OFMA)/French Monitoring Centre for Analgesic Drugs, Université Clermont Auvergne - CHU Clermont-Ferrand, 63001, Clermont-Ferrand, France.
Can J Anaesth. 2022 Aug;69(8):1042-1052. doi: 10.1007/s12630-022-02210-7. Epub 2022 Feb 28.
The Prescription Opioid Misuse Index scale (POMI) is a brief questionnaire used to assess opioid prescription misuse. In view of the increase in the prescription of opioid analgesics for chronic noncancer pain (CNCP), this tool is particularly useful during medical consultations to screen opioid misuse in patients using opioids. We sought to generate and validate a French-European translation of the POMI.
We conducted an observational, longitudinal, and multicenter psychometric study with crosscultural validation. All adult CNCP patients who were treated with opioids for at least three months, were followed in pain clinics, and spoke French were eligible. From September 2015 to November 2017, we included 163 patients and analyzed 154. We performed a pretest on a sample of representative patients to evaluate acceptability and understanding of translation. Study patients completed the POMI scale at a pain clinic (test phase), and we assessed test-retest reliability after two to four weeks by a second completion of the POMI scale at home by patients (retest phase). We subsequently explored psychometric properties of the POMI (acceptability, internal consistency, reproducibility, and external validity).
Due to poor internal consistency and reproducibility, items 4, 7, and 8 of the original POMI scale were removed, and we proposed a five-question French-European version (POMI-5F). The internal consistency of POMI-5F was good (Cronbach's α = 0.71), as was test-retest reliability (r = 0.65 [0.55-0.67]). The external validity of POMI-5F, compared with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, was moderate but significant (r = 0.45; P < 0.001). The optimal POMI-5F cut-off score to indicate misuse was 2/5 (sensitivity = 0.95 and specificity = 0.54).
We generated and validated a French-European translation of the POMI scale, POMI-5F, for use by French researchers and physicians to identify opioid misuse in CNCP patients.
处方阿片类药物滥用指数量表（POMI）是一种用于评估阿片类药物处方滥用的简短问卷。鉴于慢性非癌痛（CNCP）患者阿片类药物处方的增加，在医疗咨询中使用该工具特别有助于筛查使用阿片类药物的患者的阿片类药物滥用情况。我们旨在生成和验证 POMI 的法欧翻译版。
我们进行了一项观察性、纵向和多中心心理测量研究，并进行了跨文化验证。所有接受至少三个月阿片类药物治疗的成年 CNCP 患者，在疼痛诊所接受随访且讲法语的患者均符合条件。我们于 2015 年 9 月至 2017 年 11 月纳入了 163 名患者，并对其中 154 名患者进行了分析。我们对代表性患者进行了预测试，以评估翻译的可接受性和理解程度。研究患者在疼痛诊所完成 POMI 量表（测试阶段），然后在两周至四周后通过患者在家中再次完成 POMI 量表（重测阶段）评估重测信度。我们随后探索了 POMI 的心理测量特性（可接受性、内部一致性、可重复性和外部有效性）。
由于内部一致性和可重复性差，原始 POMI 量表的第 4、7 和 8 项被删除，我们提出了一个五项法欧版（POMI-5F）。POMI-5F 的内部一致性较好（Cronbach's α = 0.71），重测信度也较好（r = 0.65 [0.55-0.67]）。与《精神疾病诊断与统计手册》第五版相比，POMI-5F 的外部有效性中等但显著（r = 0.45；P < 0.001）。表示滥用的最佳 POMI-5F 截断值为 2/5（灵敏度 = 0.95，特异性 = 0.54）。
我们生成并验证了 POMI 量表的法欧翻译版 POMI-5F，供法国研究人员和医生用于识别 CNCP 患者的阿片类药物滥用。
